Form 4 Filing for Atea Pharmaceuticals, Inc. - Director Stock Transactions

Arthur S. Kirsch, a director at Atea Pharmaceuticals, Inc. (AVIR), reported transactions on June 18, 2026. He acquired 26,700 Restricted Stock Units (RSUs), which represent contingent rights to receive one share of Common Stock each. These RSUs vest in a single installment on the earlier of the next annual meeting after June 18, 2026, or June 18, 2027, subject to continued service. Additionally, Kirsch acquired 37,700 Stock Options (Right to Buy) with an exercise price of $4.36. These options vest monthly over twelve months following June 18, 2026, with full vesting by June 18, 2027, also contingent upon continued service. All reported transactions were direct holdings.